Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
5 participants
INTERVENTIONAL
2017-08-09
2018-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DEVICE_FEASIBILITY
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Protembo device treatment
Patients who consent to participate in the PROTEMBO SF Trial and in whom the ProtEmbo Cerebral Protection System is used or is attempted to be used.
ProtEmbo Cerebral Protection System
A catheter-based embolic deflection device will be positioned in the arch of the aorta to prevent debris liberated during the TAVR procedure from entering the three major vessels of the aortic arch.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ProtEmbo Cerebral Protection System
A catheter-based embolic deflection device will be positioned in the arch of the aorta to prevent debris liberated during the TAVR procedure from entering the three major vessels of the aortic arch.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Compatible left subclavian artery (≥ 4 mm diameter) without significant stenosis (\> 70%) and distance between the origin of left subclavian artery and valve plain is ≥ 90mm as determined by Multi-Slice Computed Tomography (MSCT) scan or equivalent imaging modality.
3. The subject and the treating physician agree that the subject will undergo the scheduled pre-procedural testing and return for all required post-procedure follow-up visits.
4. The subject has been informed of the nature of the trial, agrees to its provisions and has provided written informed consent as approved by the national or local regulatory authorities of the respective clinical site.
5. Subject is a minimum of 18 years of age.
Exclusion Criteria
2. Inadequate circulation to the left extremity as evidenced by signs of artery occlusion (modified Allen's test) or absence of radial/ brachial pulse.
3. Hemodialysis shunt, graft, or arterio-venous fistula involving the upper extremity vasculature.
4. TAVR conducted via other than transfemoral access (subclavian, axillar, transapical, transaortic, carotid or transcaval).
5. Evidence of an acute myocardial infarction ≤ 1 month before the intended treatment.
6. Aortic valve is a congenital unicuspid or bicuspid valve.
7. Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation \>3+).
8. Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days of the index procedure (unless part of planned strategy for treatment of concomitant coronary artery disease).
9. Pre-existing prosthetic heart valve in any position, prosthetic ring, or severe (greater than 3+) mitral insufficiency.
10. Blood dyscrasias as defined: Leukopenia, acute anemia, thrombocytopenia, history of bleeding diathesis or coagulopathy.
11. Hemodynamic instability requiring inotropic support or mechanical heart assistance.
12. Need for emergency surgery for any reason.
13. Severe hypertrophic cardiomyopathy with or without obstruction.
14. Severe ventricular dysfunction with LVEF ≤30%.
15. Echocardiographic evidence of intracardiac or aortic mass, thrombus, or vegetation.
16. Symptomatic or asymptomatic severe (≥ 70%) occlusive carotid disease requiring concomitant CEA/ stenting.
17. Subject has undergone carotid stenting or carotid endarterectomy within the previous 6 weeks.
18. Active peptic ulcer or upper GI bleeding within the prior 3 months.
19. A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, or clopidogrel, device component material, or sensitivity to contrast media, which cannot be adequately pre-medicated.
20. Recent (within 6 months) CVA or a TIA.
21. Renal insufficiency (creatinine \> 3.0 mg/ dL or GFR \< 30) and/ or renal replacement therapy at the time of screening.
22. Life expectancy \< 12 months due to non-cardiac comorbid conditions.
23. Subjects in whom anti-platelet and/ or anticoagulant therapy is contraindicated, or who will refuse transfusion.
24. Subjects who have active bacterial endocarditis or other active infections.
25. Currently participating in an investigational drug or another device study.
26. Subjects who have a planned treatment with any other investigational device or procedure during the study follow-up period (30 days).
27. Subjects with planned concomitant surgical or transcatheter ablation for Atrial fibrillation during the study follow-up period (30 days).
28. Any subject with a balloon valvuloplasty (BAV) within 30 days of the procedure.
29. Subject is a woman of child bearing age.
30. Patient with Heparin-Induced Thrombocytopenia Syndrome.
31. Inner diameter of aortic arch is less than 25mm.
32. Type I Aortic Arch: Distance of the origin of the innominate artery from the top of aortic arch is less than one times the diameter of left common carotid artery.
33. Brachiocephalic trunk originating from the aortic arch that splits into the bilateral subclavian arteries and a bicarotid trunk (Origin D).
Neurological:
1. Subject has active major psychiatric disease.
2. Subject has severe visual, auditory, or learning impairment and is unable to comprehend English or local language and therefore unable to be consented for the study.
3. Subjects with neurodegenerative or other progressive neurological disease or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities.
Angiographic:
1. Excessive tortuosity in the left radial/ brachial/subclavian artery preventing ProtEmbo System access and insertion.
2. Subject whose left radial/ brachial/ subclavian artery reveals significant stenosis, calcification, ectasia, dissection, or aneurysm.
Magnetic Resonance Imaging:
1. Subject Body Mass Index (BMI) precluding imaging in scanner.
2. Contraindications to MRI (subjects with any implantable temporary or permanent pacemaker or defibrillator, metal implants in field of view, metallic fragments, clips, or devices in the brain or eye before TAVR procedure).
3. Patients who have a high risk of complete AV block after TAVR, with the need of permanent pacemaker (e.g. patients with pre-existing bifascicular block or complete right bundle branch block plus any degree of AV block).
4. Planned implantation of a pacemaker or defibrillator implantation within the first 7 days after TAVR.
5. Claustrophobia precluding MRI scanning.
6. No scanner hardware, software, coil or protocol changes should occur during the course of the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Avania
INDUSTRY
Protembis GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James C. Leiter, M.D.
Role: STUDY_DIRECTOR
Avania
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Cardiology Galway University Hospital and SAOLTA Healthcare Group
Galway, County Galway, Ireland
Pauls Stradins Clinical University Hospital
Riga, , Latvia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIP_00104, Rev 02, 23 May 2017
Identifier Type: -
Identifier Source: org_study_id